gyki 52466 has been researched along with Brain Damage, Chronic in 1 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with GYKI 52466 protected rats against behavioural deficits and hippocampal neuronal damage induced by 4VO." | 1.29 | Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats. ( Block, F; Schmitt, W; Schwarz, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Block, F | 1 |
| Schmitt, W | 1 |
| Schwarz, M | 1 |
1 other study available for gyki 52466 and Brain Damage, Chronic
| Article | Year |
|---|---|
Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Brain Damage, Chronic; Brain Ischemia; Corpus Striatu | 1996 |